Premium
Romosozumab for the treatment of severe osteoporosis
Author(s) -
Chaplin Steve
Publication year - 2020
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1851
Subject(s) - medicine , osteoporosis , intensive care medicine
Romosozumab (Evenity) is a new monoclonal antibody therapy for severe osteoporosis in postmenopausal women at high risk of fracture. This article outlines its indications, clinical trial efficacy and side‐effects.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom